The biotech sought to bear this system out in STRIDES, a mid-phase, randomized, double-blinded and placebo-managed demo that evaluated the efficacy and protection of azelaprag—with and with out Eli Lilly’s blockbuster incretin cure tirzepatide—in greater than 200 men and women with